Report: Menthol-flavored cigarettes could be latest banned tobacco product
WASHINGTON — Menthol-flavored cigarettes are the latest target for tobacco opponents, according to published reports.
Reuters reported Friday that a committee of advisers to the Food and Drug Administration said in a report that banning mentholated cigarettes would benefit public health. Under legislation adopted in 2009, most flavored cigarettes already are banned.
The Food and Drug Administration will consider banning or limiting menthol when it receives the report Wednesday, though analysts have said a ban on menthol cigarettes is unlikely, Reuters reported.
Lilly issues warning over alcohol prep pads associated with Forteo
INDIANAPOLIS — Drug maker Eli Lilly is warning patients to avoid using alcohol prep pads that come with one of its osteoporosis drugs due to the risk of bacterial infections.
Lilly said Thursday that patients should not use pads made by the Triad Group contained in the black starter kits for Forteo (teriparatide [rDNA origin]). Triad is recalling prep pads due to potential contamination with Bacillus cereus, which can cause life-threatening infections in some patients. The recall does not affect the delivery device of Forteo, which is used for preventing bone fractures in men and postmenopausal women with osteoporosis.
Several companies, including Genentech and Bayer, have warned patients not to use Triad Group prep pads included with their drugs since Triad began the recall in January.
Gilead, Roche sue Natco Pharma over generic Tamiflu
NEW YORK — Drug makers Gilead Sciences and Roche are suing Indian drug maker Natco Pharma concerning a generic version of an influenza treatment, according to published reports.
Bloomberg reported that Gilead and Roche were accusing Natco of patent infringement due to its efforts to gain approval from the Food and Drug Administration for a generic version of Tamiflu (oseltamivir phosphate). Natco became the first company to file for approval of a generic version in February.
Tamiflu had sales of around $1 billion in 2009, according to Bloomberg. The patents covering Tamiflu will expire in 2016 and 2017, according to FDA data.